一周医药速览（05.05-05.09）

Group 1 - Heng Rui Medicine has officially passed the Hong Kong Stock Exchange hearing, marking a key progress in its listing process, with potential listing as early as May [1] - The listing will be Heng Rui Medicine's first external equity financing after its A-share IPO, representing a significant step in its internationalization strategy [1] Group 2 - Jiang Zhong Pharmaceutical reported stable overall development in core OTC categories such as gastrointestinal and digestive health, despite a decline in revenue due to market demand changes [2] - The company is focusing on consolidating its major products and categories while implementing various marketing initiatives [2] Group 3 - BeiGene's Q1 revenue increased by 50.2% to 8.048 billion yuan, with product revenue rising by 49.9% to 7.985 billion yuan, driven by self-developed products [3] - The global sales of its product Baiyueze® reached 5.692 billion yuan, marking a 63.7% year-on-year growth, solidifying its leadership in the hematology field [3] Group 4 - Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, is under investigation for insider trading, but this matter is unrelated to the company's stock [4] - The investigation pertains to Jiang Wei personally and will not significantly impact the company's daily operations [4] Group 5 - Novo Nordisk reported a 19% increase in Q1 sales to 78.1 billion Danish kroner, with operating profit growing by 22% to 38.8 billion Danish kroner [5] - The company is actively working to combat illegal drug compounding and expand the accessibility of its products in the U.S. market [5] - Novo Nordisk continues to advance the global launch plan for its obesity treatment, Wegovy® [5] Group 6 - Furuida's cosmetics segment generated 526 million yuan in revenue in Q1 2025, with a gross margin of 61.06% [6] - The Yilian brand achieved 250 million yuan in revenue, while the Yair Doctor brand generated 236 million yuan [6] - The Yilian spray line announced a new spokesperson, resulting in a 69% year-on-year sales increase, while the Yair Doctor brand is undergoing strategic adjustments [6]